Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine.
about
Vascular endothelial growth factor receptor-2 couples cyclo-oxygenase-2 with pro-angiogenic actions of leptin on human endothelial cells.Biological approaches to therapy of pancreatic cancer.Dynamic contrast-enhanced magnetic resonance imaging of sunitinib-induced vascular changes to schedule chemotherapy in renal cell carcinoma xenograft tumors.Bevacizumab revisited: its use in different mouse models of ocular pathologies.Pro-angiogenic activity of notoginsenoside R1 in human umbilical vein endothelial cells in vitro and in a chemical-induced blood vessel loss model of zebrafish in vivo.Mechanism-based mathematical modeling of combined gemcitabine and birinapant in pancreatic cancer cells.Hypoxia and angiogenesis in pancreatic cancer.Antitumor efficacy of combination of interferon-gamma-inducible protein 10 gene with gemcitabine, a study in murine modelInhibition of placental growth factor improves surgical outcome of glaucoma surgery.Molecular changes in pancreatic cancer.Transgenic mouse models generated by hydrodynamic transfection for genetic studies of liver cancer and preclinical testing of anti-cancer therapy.Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinibFluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells.Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo.The use of GEM models for experimental cancer therapeutics.Activated VEGFR2/KDR pathway in tumour cells and tumour associated vessels of colorectal cancer.AMA0428, A Potent Rock Inhibitor, Attenuates Early and Late Experimental Diabetic Retinopathy.Gemcitabine kills proliferating endothelial cells exclusively via acid sphingomyelinase activation.
P2860
Q33886342-47C0F5EB-7A6A-47A2-A5CA-A31A8B014F82Q33899938-77BCD344-1DA7-4B40-BA84-18FCA4B9541AQ34111200-8529BB5F-D7B7-468D-9BD3-9C3EE4090D97Q35223791-42B389DF-FF45-42FD-B3BF-DCEF79C93DC1Q35532669-C6C12925-A658-4CB2-9FCA-0A5B3B2D5337Q36094941-B7B5339C-5C29-4B25-87FD-426BC463D332Q36572752-5E2301F8-D6B9-4DAE-842C-3BF0B300E573Q36980421-D4F41CB5-092C-4F19-8951-331E893066A3Q37557535-EB496CA4-03DC-4930-8C5C-46D8A290D09AQ37614592-A87D3B20-9C7C-48A4-BB03-427ED98719FDQ38556534-02D6F7FD-3188-456C-A3E3-3197E0AFACDFQ38572743-84D61613-E570-42C6-A88C-2356F2288291Q40391830-811AC560-76F4-48E9-88AF-D1780496D327Q41872813-D5C60752-27D7-45A9-9962-600E09DA292CQ43127685-EC602CCC-F329-4C25-857C-77223C399E97Q46990483-C373DF7D-2B55-438C-8288-073F0533E6B8Q49037118-CFAE346E-4C0F-4C82-BA46-B97ACEDF2B5EQ53478020-A3487B9E-4430-42FC-BF65-99F16D48A226
P2860
Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Antiangiogenic versus cytotoxi ...... ase inhibitor and gemcitabine.
@en
type
label
Antiangiogenic versus cytotoxi ...... ase inhibitor and gemcitabine.
@en
prefLabel
Antiangiogenic versus cytotoxi ...... ase inhibitor and gemcitabine.
@en
P2093
P921
P1476
Antiangiogenic versus cytotoxi ...... nase inhibitor and gemcitabine
@en
P2093
Alessandro Fasciani
Anna Fioravanti
Daniela Campani
Elena Boschi
Franco Mosca
Gabriele Marangoni
Guido Bocci
Irene Esposito
Mario Del Tacca
P356
10.1016/J.EJPHAR.2004.07.062
P407
P577
2004-09-01T00:00:00Z